EQ and Estrogen: Why Boldenone Crashes Your E2 (and How to Fix It)

You started your Equipoise cycle expecting lean gains and better cardio. Four weeks in, your joints ache, your mood is flat, your libido is gone, and your skin feels like paper. You dropped your AI two weeks ago and things are still getting worse.

Welcome to the most misunderstood compound interaction in bodybuilding: boldenone's estrogen suppression effect.

EQ does not just "aromatize less than testosterone." It actively suppresses your estradiol through a metabolite that functions as a suicide aromatase inhibitor. And if you are running it at the wrong ratio, or stacking it with an actual AI, you will crash your E2 harder than if you took too much letrozole.

This guide covers the mechanism, the community ratios that work, the bloodwork you need, and how to rescue a crashed E2 situation.

How boldenone suppresses estrogen

The standard explanation you will hear is that "EQ aromatizes at about 50% the rate of testosterone." This comes from William Llewellyn's Anabolics reference guide and has been repeated across forums for 20 years. It is misleading.

The real mechanism is more aggressive than simple low aromatization. Boldenone is metabolized into two key compounds:

1. Androsta-1,4-diene-3,17-dione (ADD/boldione): a precursor that can be further metabolized into ATD
2. Androsta-1,4,6-triene-3,17-dione (ATD): a known suicide (irreversible) aromatase inhibitor that permanently inactivates aromatase enzyme molecules

ATD was characterized as a potent irreversible aromatase inhibitor by Brodie et al. in 1983, published in the Journal of Medicinal Chemistry (Brodie et al., 1983). "Suicide inhibitor" means that once ATD binds to the aromatase enzyme, that enzyme molecule is permanently destroyed. Your body must synthesize new aromatase to resume estrogen production.

This is the same mechanism as letrozole and exemestane. Boldenone essentially comes with a built-in AI.

The estrone problem

There is an additional complication that rarely gets discussed. Boldenone may shift estrogen metabolism toward estrone (E1) rather than estradiol (E2). Standard blood tests measure E2 specifically. If your body is producing estrone instead, your E2 reading will look low even though total estrogenic activity might be adequate.

This may explain why some users report E2 lab values in the low teens but do not experience full-blown crashed E2 symptoms. Their estrone levels are partially compensating.

Unfortunately, estrone is rarely included in standard bloodwork panels. If your E2 reads low on EQ but your symptoms are mild, this could be why.

The ratio debate: how much testosterone do you need?

This is the most debated topic in every EQ thread on every forum. The answer depends on how much you personally aromatize.

2:1 Test:EQ (e.g., 600 mg Test / 300 mg EQ)

The most conservative ratio. Recommended for:

• First-time EQ users
• Users who aromatize lightly (never needed an AI on test-only cycles)
• Users who have crashed E2 before and know how bad it feels

This ratio provides enough testosterone to maintain healthy E2 even with EQ's AI-like effect. The downside is you get less of EQ's unique benefits (vascularity, appetite increase, endurance) at the lower dose.

3:2 Test:EQ (e.g., 600 mg Test / 400 mg EQ)

The middle ground. This is the most commonly recommended ratio across experienced communities. It works for the majority of users who have moderate aromatization rates. Most users can maintain E2 in the 20-35 pg/mL range at this ratio without an AI.

1:1 Test:EQ (e.g., 500 mg Test / 500 mg EQ)

Only appropriate for heavy aromatizers: users who normally need an AI when running 500+ mg testosterone alone. These users have enough aromatase activity that EQ's suppression brings them into a healthy range rather than crashing them.

If you are considering 1:1, you should have prior bloodwork on a test-only cycle showing E2 above 60-70 pg/mL at comparable testosterone doses.

What if you have no idea how much you aromatize?

Start at 2:1 and get bloodwork at 6 weeks. If your E2 is comfortably in range (25-45 pg/mL), you can adjust the ratio toward 3:2 on your next cycle. Never start at 1:1 without prior data.

The bloodwork protocol

EQ's long undecylenate ester (half-life ~14 days) means it takes 6-8 weeks to fully saturate. Your bloodwork timeline needs to account for this.

Baseline (before first injection)

Week 6-8 (first on-cycle check)

This is the critical check. EQ should be approaching steady state, and estrogen effects will be apparent.

Priority markers:

• E2 (sensitive): Is it dropping? If below 20 pg/mL with symptoms, your ratio is too high in EQ
• Haematocrit: Has it risen 3-5+ points? EQ-driven erythropoiesis starts early
• Ferritin: Already declining? Accelerated RBC production burns through iron stores

Week 12-16 (mid-cycle)

Full panel repeat. By now, all effects are fully expressed.

Watch for:

• E2 continuing to drop (cumulative ATD effect)
• HCT above 52%: consider blood donation or dose reduction
• HDL suppression (EQ hits lipids harder than nandrolone in some users)
• Creatinine elevation: likely artefactual from muscle mass, but confirm with cystatin C if concerned

Post-cycle (4-6 weeks after last EQ injection)

Due to the long ester, EQ continues suppressing E2 and stimulating erythropoiesis for weeks after your last injection. Do not start PCT until the compound has substantially cleared.

Critical note: If you are blast-and-cruise, your E2 may remain suppressed on your cruise dose of testosterone for 4-6 weeks after dropping EQ. Be patient before making further adjustments.

The erythropoiesis problem

EQ is arguably the most erythropoietic anabolic steroid per unit of androgenic activity. The mechanism involves sustained EPO upregulation, hepcidin suppression, and direct androgen receptor stimulation in bone marrow (Shalaby & Shanab, 2014).

Expect haematocrit to rise 5-8 percentage points above baseline over 8-12 weeks at 200-400 mg/week. This is significantly more than testosterone alone.

The iron paradox on EQ: As your body ramps up red blood cell production, it burns through iron stores rapidly. You can end up with elevated HCT (too many red cells) while simultaneously having low ferritin (depleted iron). This is the iron paradox described in our Iron Paradox on TRT article, and EQ accelerates it dramatically.

HCT management on EQ

For detailed hematocrit management protocols, see our Lower Hematocrit on TRT guide.

EQ and kidney markers: the creatinine trap

There is a case report of apparent renal disease in a 37-year-old male using boldenone that resolved completely after discontinuation (Seaman et al., 2010). Animal studies show boldenone can cause glomerular damage (Alm-Eldeen & Tousson, 2012), and a systematic review found increased renal parenchyma thickness in AAS-using bodybuilders (Parente Filho et al., 2019).

However, there is an important confound: boldenone increases muscle mass, which increases creatine turnover, which elevates serum creatinine. Standard eGFR calculations based on creatinine will therefore underestimate your kidney function.

Solution: Use cystatin C instead of (or alongside) creatinine for kidney assessment on EQ. Cystatin C is not affected by muscle mass and gives a more accurate picture of actual glomerular filtration rate. For a deeper explanation, see our Cystatin C guide.

EQ and lipids

Animal studies demonstrate that boldenone significantly increases total cholesterol, LDL, and triglycerides while decreasing HDL (Abdel-Reheim, 2021). Interestingly, grape seed proanthocyanidin extract showed protective effects against boldenone-induced cardiac toxicity in animal models (Tousson et al., 2018).

In practice, EQ's lipid impact falls between testosterone (mild) and oral AAS like Winstrol (severe). The long ester means lipid changes develop gradually and take weeks to recover after cessation.

Practical advice: If your HDL drops below 30 mg/dL or your LDL rises above 160 mg/dL mid-cycle, consider reducing your EQ dose. For supplement strategies, see our Cholesterol on Steroids and On-Cycle Support Protocol guides.

How to rescue crashed estrogen on EQ

If you are already in a low E2 situation on EQ, here is the protocol:

Step 1: Confirm with bloodwork

Get a sensitive E2 assay (LC-MS/MS). Do not adjust doses based on symptoms alone. Symptoms of low and high E2 overlap significantly (mood changes, libido issues, water retention changes).

Step 2: Drop or reduce EQ

Due to the 14-day half-life, simply dropping EQ will not fix your E2 quickly. Expect 3-4 weeks before you notice improvement, and 6-8 weeks for full clearance.

• Mild crash (E2 15-20 pg/mL with symptoms): Reduce EQ by 50%, recheck in 4 weeks
• Severe crash (E2 below 15 pg/mL): Discontinue EQ entirely

Step 3: Increase testosterone

Temporarily increasing your testosterone dose by 25-50% can help restore aromatization substrate. More testosterone means more available for conversion to E2.

Step 4: Wait

This is the hard part. The undecylenate ester is long-acting. Even after your last injection, active boldenone continues releasing from the depot site for weeks. There is no quick fix.

What about exogenous estradiol?

Some advanced users add pharmaceutical estradiol (patches, gel, or oral) to directly replace suppressed E2. This bypasses the aromatization pathway entirely. It works, but it introduces another variable to manage and is not recommended unless you have experience monitoring E2 closely.

MENT (trestolone) is another option used by some experienced users. MENT aromatizes heavily and can restore E2 quickly. However, it is a potent compound with its own monitoring requirements and is not a casual fix.

The complete EQ monitoring panel

Here is everything you should test on a boldenone cycle, in order of priority:

Key takeaways

• Boldenone produces ATD, a suicide aromatase inhibitor. It does not just "aromatize less"; it actively suppresses your estrogen production
• Start with a 2:1 Test:EQ ratio if you have never used EQ before. Adjust toward 3:2 only after confirming E2 is stable on bloodwork
• Never combine EQ with a pharmaceutical AI unless sensitive E2 bloodwork confirms you need one
• EQ is the most erythropoietic AAS: monitor haematocrit every 6-8 weeks and watch for iron depletion
• Use cystatin C instead of creatinine for kidney assessment on EQ; muscle mass confounds standard eGFR
• Crashed E2 on EQ takes 4-8 weeks to recover due to the long undecylenate ester. There is no quick fix
• Always use the sensitive E2 assay (LC-MS/MS), not the standard immunoassay

---

References

1. Brodie, A. M., Garrett, W. M., Hendrickson, J. R., et al. (1983). Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Journal of Medicinal Chemistry, 26(1), 118-122. DOI

2. Shalaby, A. M. & Shanab, O. A. (2014). The effect of boldenone undecylenate on haematological and biochemical parameters in rabbits. Global Veterinaria, 12(5), 714-720. PubMed

3. Abdel-Reheim, E. S. (2021). Boldenone undecylenate-mediated hepatorenal impairment by oxidative damage and dysregulation of heat shock protein 90 and androgen receptor signaling in rat. Frontiers in Pharmacology, 12, 651497. DOI

4. Tousson, E., El-Moghazy, M., Massoud, A., & Akel, A. (2018). Histopathological and immunohistochemical changes in the testes of rabbits after injection of boldenone undecylenate with evaluation of the protective role of grape seed proanthocyanidin. Oxidative Medicine and Cellular Longevity, 2018, 9434385. DOI

5. Ho, E. N., Yiu, K. C., Wan, T. S., Stewart, B. D., & Watkins, K. L. (2007). Detection of anti-doping markers in equine plasma after administration of boldenone undecylenate. Journal of Veterinary Pharmacology and Therapeutics, 30(3), 280-283. PubMed

6. Seaman, M. E., Mott, J. D., & Sephel, G. C. (2010). Apparent renal disease due to elevated creatinine levels associated with the use of boldenone in a bodybuilder. Clinical Nephrology, 74(6), 474-476. PubMed

7. Alm-Eldeen, A. A. & Tousson, E. (2012). Deterioration of glomerular endothelial surface layer and the alteration in the renal function after a growth promoter boldenone injection in rabbits. Human & Experimental Toxicology, 31(5), 465-472. PubMed

8. Parente Filho, S. L., Gomes, P. E., Forte, G. A., et al. (2019). Kidney disease associated with androgenic-anabolic steroids and vitamin supplements abuse: be aware! BMC Nephrology, 20, 383. DOI

9. de Ronde, W. & Smit, D. L. (2022). The HAARLEM study: a one-year prospective cohort study in 100 male amateur athletes using anabolic androgenic steroids. Current Opinion in Endocrinology, Diabetes and Obesity, 29(6), 560-565. PubMed

10. Llewellyn, W. (2011). Anabolics (10th ed.). Molecular Nutrition.